Visit CURE at http://curenet.org and CURE BioScience Explorations at http://bioscienceexplorations.org
Nov/Dec 2011
 



Events Column
 
Find talented Pfizer employees at the Pfizer Career Center.
 
11/15 4:00 pm - 6:00 pm
CURE/Yale BioHaven with Crossroads Venture Group presents 'Healthcare IT: Challenges and Opportunities.' Panel discussion. Yale Anlyan Center, 300 Cedar Street, New Haven. more
 
12/6 5:45 pm - 7:30 pm
CURE Holiday Party. 'Best networking in town.' Café George, 300 George Street, New Haven.
 
1/25 4:00 pm - 6:00 pm
CURE/Yale BioHaven presents Thetis Pharmaceuticals. Yale Anlyan Center, 300 Cedar Street, New Haven. more
 
2/28 4:00 pm - 6:00 pm
CURE/Yale BioHaven with Crossroads Venture Group presents 'Personalized Medicine: How Far Off?' Panel discussion. Yale Anlyan Center, 300 Cedar Street, New Haven. more
 
3/29 4:00 pm - 6:00 pm
CURE/Yale BioHaven presents Soft Tissue Regneration, Inc. Yale Anlyan Center, 300 Cedar Street, New Haven. more
 
4/13
Yale Healthcare Conference. Omni Hotel, New Haven more
 
4/26 4:00 pm - 6:00 pm
CURE/Yale BioHaven presents Chondrogenics, Inc. Yale Anlyan Center, 300 Cedar Street, New Haven. more
 
9/10-9/11 BioPharm America 2011: 4th Annual International Partnering Conference. Westin Boston Waterfront, Boston, MA. more
 
3Q 2011: CT life sciences attract further $10 million

The Life Sciences sector in Connecticut drew over $10 million of new investment capital in the third quarter of 2011, according to The MoneyTree® Report, issued quarterly by PricewaterhouseCoopers and the National Venture Capital Association, based on data from Thomson Reuters.

Details are as follows.

CT Life Science Venture Capital Investments: Representative Investments by Quarter and Type

 

 

Company

$
2011 Biotechnology Q3 BioRelix, Inc., Inc. 3,644,000
2011 Biotechnology Q3 Cara Therapeutics, Inc. 7,000,000
       
2011 Biotechnology Q2 Cara Therapeutics, Inc. 3,000,000
       
2011 Medical Devices
 Q1 Advanced Orthopedic Technologies
 50,000
2011 Medical Devices
 Q1 SurgiQuest, Inc. 19,999,900
2011 Biotechnology Q1 CMD Bioscience LLC 150,000
2011 Biotechnology Q1 AlloStem Therapeutics
 75,000
2011 Biotechnology Q1
 Rib-X Pharmaceuticals
 20,000,000




2010 Biotechnology Q4 Helix Therapeutics 2,500,000
2010 Medical Devices Q4 Affinimark Technologies 1,247,000
2010 Biotechnology Q3 Cara Therapeutics 15,000,000
2010 Biotechnology Q3 Ikonisys 3,804,900
2010 Medical Devices Q3 Affinimark Technologies 425,000
2010 Biotechnology Q3 Metagenomix 257,000
2010 Medical Devices Q3 Advanced Orthopedic Technologies 50,000
2010 Medical Devices Q2 EipEp 1,500,000
2010 Medical Devices Q2 Soft Tissue Regeneration 3,500,000
2010 Biotech Q2 BioRelix 552,000
2010 Biotech Q2 Metagenomix 700,000
2010 Biotech Q2 Cytogel Pharma 2,200,000
2010 Biotech Q2 Mira Dx 4,000,000
2010 Biotech Q2 CyVek 4,013,000
2010 Biotech Q1 Metagenomix 400,000
2010 Biotech Q1 FMP Products 500,000
2010 Biotech Q1 Axerion Therapeutics 750,000
2010 Biotech Q1 Kolltan Pharmaceuticals 10,000,000
2010 Other Q1 Ion Torrent Systems 10,000,000
       
2009 Medical Devices Q4 HistoRx 3,161,000
2009 Biotech Q4 Rib-X 5,284,000
2009 Biotech Q4 Affomix 1,854,000
2009 Biotech Q3 Kolltan 5,000,000
2009 Biotech Q3 BioRelix 3,600,000
2009 Biotech Q2 Marinus 20,412,000
2009 Biotech Q1 Rib-X Pharmaceuticals 25,000,200
2009 Biotech Q1 Affomix Corporation 5,211,000
2009 Biotech Q1 Optherion, Inc. 5,000,000
       
2008 Medical Devices Q4 SurgiQuest, Inc. 9,500,000
2008 Medical Devices Q4 Carigent Therapeutics, Inc. 600,000
2008 Biotechnology Q3 Cara Therapeutics, Inc. 12,300,000
2008 Biotech Q2 Optherion, Inc. 15,000,000
2008 Medical Devices Q2 SurgiQuest, Inc. 4,750,000
2008 Biotech Q1 Pequot EnzymeRx 14,000,000
2008 Biotech Q1 Affomix 7,000,000



2,000,000
2007 Biotech Q4 Carigent Therapeutics 2,000,000
2007 Biotech Q4 Optherion 26,999,700
2007 Biotech Q3 REN Pharmaceuticals   1,000,000
2007 Biotech Q3 Genomas 2,500,000
2007 Biotech Q3 BioRelix 25,750,200
2007 Biotech Q3 Optherion 10,000,000
2007 Biotech Q2 Spine Wave 45,000,200
2007 Biotech Q1 Cara Therapeutics 5,000,000
2007 Biotech Q1 RainDance Technologies 23,655,000




2007 Medical Devices Q4 HistoRx 2,280,000
2007 Medical Devices Q4 Ikonisys 20,000,000
2007 Medical Devices Q3 HistoRx 6,552,000
2007 Medical Devices Q2 Applied Spine Technologies 13,000,000
2007 Medical Devices Q1 Applied Spine Technologies 15,000,000
2007 Medical Devices Q1 Stevens Proof of Concept 500,000

CT Life Science Venture Capital Investments by Type
2006
2007
2008

Deals $ Deals $ Deals $
Biotech 9 146,600,800 9 145,589,300 4 24,300,400
Medical Devices 2 15,000,000 7 69,332,000 5 19,387,000
Other*

1 23,655,000

TOTAL (Life Sciences) 11 161,600,800 17 238,576,300 9 43,687,400

* RainDance Technologies of Guilford

CT Life Science Venture Capital Investments by Type (cont.)


 2009 2010

Deals $ Deals $
Biotech 10 106,861,200 15 57,322,900
Medical Devices 4 4,211,000 6 6,397,000
Other*     1 10,000,000
TOTAL (Life Sciences) 14 111,072,200 21 73,719,900

* ION Torrent Systems of Guilford

CT Life Science Venture Capital Investments by Type (cont.)

Q1 2011

Q2 2011


Deals

$

Deals

$

Biotech

3

20,225,000

1

3,000,000

Medical Devices

3

20,200,000

0

 

Total (Life Sciences)

6

42,425,000

1

3,000,000


Q3 2011

Q4 2011


Deals

$

Deals

$

Biotech

2

10,644,000



Medical Devices





TOTAL (Life Sciences)

2

10,644,000



CT Venture Capital Investments by Quarter


Quarter
# of Deals		 Investment Amount Life Sciences Amount % Life Sciences
Q3 2011 9 $43.6 million $10.6 million 24%
Q2 2011 13 $20.3 million $10.4 million 51%
Q1 2011 22 $55.3 million
 $40.4 million
 73%
Q4 2010 14
 $37.3 million $3.8 million 10%
Q3 2010 14
 $22.8 million
 $8.9 million
 58%
Q2 2010 16 $24.6 million $16.5 million 39%
Q1 2010 15 $131.9 million $24.2 million 18%
Note: Q1 2010 Total Investment Amount includes a single deal in Financial Services of $85.8 million (Pierpont Securities). Excluding that one deal, the relative investments would be:
Q1 2010 14 $46.1 million
 $24.2 million
 52%
Q4 2009 13 $19.1 million $10.3 million 54%
Q3 2009 10 $17.5 million $8.6 million 49%
Q2 2009 12 $49.1 million $21.9 million 45%
Q1 2009 7 $73.7 million $70.2 million 95%
Q4 2008 9 $15.1 million $10.1 million 67%
Q3 2008 11 $50.6 million $12.3 million 24%
Q2 2008 8 $31.5 million $10.7 million 34%
Q1 2008 8 $18.1 million $7.0 million 39%
Q4 2007 13 $78.1 million $61.3 million 81%
Q3 2007 9 $36.8 million $19.1 million 52%
Q2 2007 9 $107.1 million $88.5 million 83%
Q1 2007 7 $ 51.7  million $46.0 million 89%
Q4 2006 6 $39.3 million $20.1 million 52%
Q3 2006 10 $56.4 million $21.5 million 38%
Q2 2006 9 $111.7 million $68.7 million 62%
Q1 2006 6 $56.6 million $51.3 million 91%

CT Venture Capital Investments by Year

Year #  of Deals Investment Amount Life Sciences Amount % Life Sciences
2010 59 $216.6 million $53.4 million 25%
2009 39 $157.4 million $111.1 million 71%
2008 37 $121.2 million $43.7 million 36%
2007 37 $273.7 million $214.9 million 79%
2006 31 $263.9 million $161.6 million 61%
2005 31 $192.8 million    
2004 32 $195.9 million    
2003 34 $203.8 million    
2002 38 $182.7 million    
2001 70 $549.8 million    
 




Copyright 2011 © Connecticut United for Research Excellence. All rights reserved. Visit CURE at http://curenet.org and CURE BioScience Explorations at http://bioscienceexplorations.org
Click here for Archive of back issues.
Newsletter developed and edited by HarveyMalis Communications LLC, Guilford, Conn.

Managing Your Subscriptions
Click on the "Manage your subscription" link below and then on "Edit Your Profile." To subscribe to a publication, type a "y" in the box to the right of the publication name. To unsubscribe, leave the box blank.